Page 19,   line 13, please replace "acdi" with --acid--.

Page 21,   line 29, please replace "skilied" with --skilled--;

line 30, please replace "enyzmatic" with --enzymatic--.

Page 25,   line 32, please replace "effecting" with --affecting--.

Page 28,   line 13, please replace "spleen.y" with --spleen.--.

Page 31,   line 6, after "48" please insert --and--;

line 22, please replace "ng/mg" with --ng/mg)--;

line 26, please replace "ng/ml" with --ng/ml)--.

Page 32,   line 11, please replace "meonatal" with --neonatal--;

line 26, please replace "Shingomyelin(SM):EPC:CHOL" with

--Sphingomyelin(SM):EPC:CHOL--;

Page 33,   line 1, please replace "of ^{32}P" with --of ^{32}P--;

line 2, between "i.v." and "made," please insert --was--.

IN THE CLAIMS:

Please cancel claims 1-61.

Please add new claims 62-83:

---

1   --62. A method of treating a neoplasia in a mammal, said method comprising

2   administering to said mammal a pharmaceutical composition comprising a polyethylene glycol

3   (PEG)-ceramide conjugate, a lipid, and a nucleic acid catalyst, whereby a therapeutic result is

4   attained.

1   63. The method of claim 62, wherein the administration of said composition

2   results in a decrease in the expression of an RNA associated with said neoplasia in said

3   mammal.

1   64. The method of claim 62, wherein said neoplasia comprises a tumor.

1   65. The method of claim 62, wherein the administration is a systemic

2   administration.

1   66. The method of claim 62, wherein said composition further comprises
2 phosphatidyl choline.

1   67. The method of claim 66, wherein said phosphatidyl choline is egg yolk
2 phosphatidyl choline.

1   68. The method of claim 62, wherein said composition further comprises
2 cholesterol.

1   69. The method of claim 62, wherein said nucleic acid catalyst has an
2 endonuclease activity.

1   70. The method of claim 62, wherein said nucleic acid catalyst comprises a
2 ribonucleotide or a deoxyribonucleotide.

1   71. The method of claim 62, wherein said nucleic acid catalyst comprises a
2 hammerhead motif.

1   72. The method of claim 62, wherein said lipid is a cationic lipid.

1   73. The method of claim 72, wherein said cationic lipid is DODAC or DOTAP.

1   74. The method of claim 62, wherein said PEG-ceramide conjugate comprises a
2 fatty acid group having eight carbon atoms.

1   75. The method of claim 62, wherein said PEG-ceramide conjugate comprises a
2 fatty acid group having fourteen carbon atoms.

1   76. The method of claim 62, wherein said PEG-ceramide conjugate comprises a
2 fatty acid group having twenty carbon atoms.

1   77. The method of claim 62, wherein said nucleic acid catalyst specifically
2 cleaves vascular endothelial growth factor receptor (VEGF-R) RNA.